Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01974895 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
A Phase 2 study of Influenza, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 316
- Enrollment target
- 12
- Study locations
NCT01974895 is a Phase 2 study of Influenza that has completed, run by GlaxoSmithKline. The registered enrollment target is 316 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT01974895, a Phase 2 study of Influenza, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 316 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone® (TIV) in children 6 to 35 months of age.
Conditions Studied
Interventions
- BIOLOGICAL FluLaval® Quadrivalent
- BIOLOGICAL Fluzone®
Study Locations (12)
California
- GSK Investigational Site - Sacramento
- GSK Investigational Site - West Covina
Massachusetts
- GSK Investigational Site - Fall River
- GSK Investigational Site - Woburn
South Carolina
- GSK Investigational Site - Barnwell
- GSK Investigational Site - Cheraw
Florida
- GSK Investigational Site - Altamonte Springs
Michigan
- GSK Investigational Site - Stevensville
New York
- GSK Investigational Site - Syracuse
Ohio
- GSK Investigational Site - Cleveland
Pennsylvania
- GSK Investigational Site - Hermitage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2013-10-23 |
| Est. Completion | 2014-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01974895
The ClinicalTrials.gov registry entry for NCT01974895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which FluLaval® Quadrivalent is the first listed.
NCT01974895 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, Massachusetts, South Carolina.
Frequently Asked Questions
What is clinical trial NCT01974895 about?
NCT01974895 is a clinical study titled "Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age". The purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone® (TIV) in children 6 to 35 months of age.
What is the current status of trial NCT01974895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 316 participants. The study started on 2013-10-23. Estimated completion is 2014-07-03.
What conditions does trial NCT01974895 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01974895?
The interventions under investigation include: FluLaval® Quadrivalent (BIOLOGICAL), Fluzone® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01974895?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01974895 being conducted?
This trial has 12 study locations across California, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.